… of DRV/c (a single-tablet regimen containing 800 mg of darunavir and 150 mg of cobicistat)
per day for 5 days, while participants in the control group did not receive oral antiviral drugs. …

… patients with mild‐to‐moderate COVID‐19 and at high risk for progression … oral antiviral
agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID‐19…

… COVID-19 test were selected from medical records held by the Hospital Authority of Hong
Kong. We included patients with non-oxygen-dependent COVID-19 … no oral antiviral treatment (…

… lack of spike protein variant resistance challenges, SARS-CoV-2 M pro inhibition
represents an attractive small-molecule approach for an oral antiviral therapy to treat COVID-19. …

… oral medications for non-hospitalised patients with COVID-19. Currently there are five
medicinal products authorised for treating patients with COVID-19 … ) and one antiviral (remdesivir). …

… Dysgeusia is the first recognized oral symptom of novel coronavirus disease (COVID-19).
In this review article, we described oral lesions of COVID-19 patients. We searched PubMed …

… smallmolecule antiviral therapies were considered the emergency responders on the
COVID‐19.… Only very recently, the oral antiviral candidate Paxlovid™ (PF07321332 + ritonavir), …

… 2 (SARS-CoV-2), great progress has been made in the research and development of oral
small… At present, the research and development of oral small-molecule drugs for COVID-19 are …

… COVID-19 therapies and multi-drug treatment, it is believed that some oral conditions could
be aggravated by COVID-19 … These anti-viral drugs may be responsible for side effects (<2%) …

… for safe and efficacious antiviral drugs to improve outcomes for COVID-19 patients. Understanding
SARS-… A novel oral antiviral agent remains lacking. The discussed antivirals have not …